Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IM96 CAR-T cells

Next Previous
Drug Profile

IM96 CAR-T cells

Alternative Names: Anti-GUCY2C chimeric antigen receptor T-cell; IM96; IM96 CAR-T cells - Beijing Immunochina Medical Science and Technology

Latest Information Update: 23 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Immunochina Medical Science and Technology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer
  • No development reported Digestive system neoplasms; Pancreatic cancer

Most Recent Events

  • 23 Feb 2026 IM96 CAR-T cells is still in phase I trial in Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT06718738)
  • 13 Feb 2026 Beijing Immunochina Medical Science & Technology plans a phase I trial for Adenocarcinoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (Parenteral, Infusion) in March 2026 (NCT07406984)
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top